Aster DM Healthcare Limited (“Company”), one of the largest private healthcare service providers which operate in multiple GCC states based on number of hospitals and clinics, according to the Frost & Sullivan Report, and an emerging healthcare player in India, will be launching its initial public offering (“IPO” or the “Offer”) which is scheduled to open on February 12, 2018 and close on February 15, 2018 with a price band of Rs.180 – Rs. 190 per Equity Share of face value of Rs. 10 each of the Company (the “Equity Shares”). The anchor investor allocation will be a day prior to the Bid/Offer Opening Date i.e. February 09, 2018.
The IPO consists of a fresh issue of up to [●] Equity Shares aggregating up to Rs. 7,250 million (“Fresh Issue”) and an Offer for Sale of up to 13,428,251 Equity Shares of the Company by the Promoter, Union Investments Private Limited (“UIPL” or the “Selling Shareholder”).
The Company proposes to utilize the Net Proceeds of the Fresh Issue for (i) repayment and/or pre-payment of debt; (ii) purchase of medical equipment; and (iii) general corporate purposes (collectively, referred to herein as the “Objects”).
In terms of Rule 19(2)(b)(iii) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), this is an Offer for at least 10% of the post-Offer paid-up equity share capital of the Company.
Kotak Mahindra Capital Company Limited, Axis Capital Limited and Goldman Sachs (India) Securities Private Limited are the Global Co-ordinators and Book Running Lead Managers to the Offer (“GCBRLMs”) and ICICI Securities Limited, JM Financial Limited* & YES Securities (India) Limited are the Book Running Lead Managers (“BRLMs”, and together with the GCBRLMs, the “Managers”) to the Offer. The Registrar to the Offer is Link Intime India Private Limited.
The Offer is being made in accordance with Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended (the “SEBI ICDR Regulations”), through the Book Building Process wherein 50% of the Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”), provided that the Company in consultation with the Selling Shareholder and the Managers may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, out of which one-third shall be reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Offer Price, in accordance with the SEBI ICDR Regulations. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price.
Further, not less than 15% of the Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential investors, other than Anchor Investors, are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank accounts which will be blocked by the Self Certified Syndicate Banks (“SCSBs”). For details, see “Offer Procedure” on page 599.
The Offer will constitute xx% of the post Offer paid-up Equity Share capital of the Company.
The Equity Shares of the Company are proposed to be listed on BSE Limited and National Stock Exchange of India Limited.
